Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Oxford Biomedica plc    OXB   GB00BDFBVT43

OXFORD BIOMEDICA PLC

(OXB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/20/2020 10/21/2020 10/22/2020 10/23/2020 10/26/2020 Date
802(c) 784(c) 790(c) 819(c) 827(c) Last
107 793 46 588 231 994 105 713 134 571 Volume
-1.47% -2.24% +0.77% +3.67% +0.98% Change
More quotes
Financials
Sales 2020 84,5 M 110 M 110 M
Net income 2020 -3,28 M -4,27 M -4,27 M
Net cash position 2020 24,2 M 31,5 M 31,5 M
P/E ratio 2020 -190x
Yield 2020 -
Sales 2021 116 M 151 M 151 M
Net income 2021 5,75 M 7,47 M 7,47 M
Net cash position 2021 20,2 M 26,3 M 26,3 M
P/E ratio 2021 125x
Yield 2021 -
Capitalization 673 M 879 M 876 M
EV / Sales 2020 7,68x
EV / Sales 2021 5,62x
Nbr of Employees 584
Free-Float 83,7%
More Financials
Company
Oxford BioMedica Plc is a gene and cell therapy company. The Company and its subsidiaries has developed lentiviral vector delivery platform (LentiVector), which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, liver and central... 
More about the company
Notations Surperformance© of Oxford Biomedica plc
Trading Rating : Investor Rating :
More Ratings
All news about OXFORD BIOMEDICA PLC
10/06OXFORD BIOMEDICA : notes Axovant's positive six-month follow-up from second coho..
PU
10/06OXFORD BIOMEDICA : notes Axovant's positive six-month follow-up from second coho..
AQ
10/06Oxford Biomedica notes Axovant's positive six-month follow-up from second coh..
GL
10/06OXFORD BIOMEDICA : receives MHRA approval for fourth manufacturing suite in Oxbo..
PU
09/17OXFORD BIOMEDICA : Interim results for the six months ended 30 june 2020
AQ
09/17Oxford biomedica plc interim results for the six months ended 30 june 2020
GL
09/17OXFORD BIOMEDICA : OXB Interim Results FY20 RNS FINAL.pdf
PU
09/17OXFORD BIOMEDICA : interim results for thesix months ended 30 June 2020
PU
09/14ASTRAZENECA : London stocks gain as AstraZeneca resumes vaccine trials
RE
09/03AstraZeneca signs deal with Albany Molecular to produce COVID-19 vaccine cand..
RE
09/01Oil rises on strong factory activity, crude drawdown forecast
RE
09/01LONDON STOCK EXCHANGE : FTSE 100 falls to 15-week low after best August since 20..
RE
09/01FACTBOX : AstraZeneca's potential coronavirus vaccine
RE
09/01ASTRAZENECA : bolsters COVID-19 vaccine supply with new deal
RE
09/01AstraZeneca bolsters COVID-19 vaccine supply with new deal
RE
More news
News in other languages on OXFORD BIOMEDICA PLC
09/17Qu'importe le flocon pourvu qu'on ait l'ivresse
09/17EN DIRECT DES MARCHES : Unibail, LVMH, EssilorLuxottica, Alstom, Spotify, Sony, ..
05/14AVIS D'ANALYSTES DU JOUR : Accor, Alcon, Burberry, Elior, Europcar, Icade, Lonza..
05/14Powell plombe l'ambiance
04/28AVIS D'ANALYSTES DU JOUR : Accor, Adidas, Ambu, Carrefour, Ferrari, HelloFresh, ..
More news
Chart OXFORD BIOMEDICA PLC
Duration : Period :
Oxford Biomedica plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXFORD BIOMEDICA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 1 012,88 GBX
Last Close Price 819,00 GBX
Spread / Highest target 77,0%
Spread / Average Target 23,7%
Spread / Lowest Target -29,2%
EPS Revisions
Managers
NameTitle
John Andrew Dawson Chief Executive Officer & Executive Director
Frederic Roch Doliveux Non-Executive Chairman
Nick Page Chief Operating Officer
Stuart Paynter Chief Financial Officer & Director
Kyriacos Mitrophanous Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXFORD BIOMEDICA PLC26.98%879
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097